Approval Alert | Momelotinib for Myelofibrosis With Anemia

If momelotinib receives approval in the European Union, it will become the only agent for the treatment of myelofibrosis coupled with moderate to severe anemia.

With the approval of momelotinib by the FDA, the updated use for its role in myelofibrosis will potentially change clinical practice, according to Ruben Mesa, MD.

Patients with myelofibrosis and anemia can now receive treatment with momelotinib following the agent’s approval by the FDA based on results from the phase 3 MOMENTUM trial.

Lead study author Ruben Mesa, MD, discusses findings from the MOMENTUM trial assessing the use of momelotinib in the treatment of myelofibrosis.